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Background. LGE2 is produced by the cyclooxygenase- or free
radical-mediated modification of arachidonate and is formed
during the oxidation of low density lipoprotein (LDL) with
subsequent adduction to lysine residues in apo B. We have
developed a sensitive enzyme-linked sandwich immunosorbent
assay (ELISA) for detection and measurement of LGE2-protein
adducts as an estimate of oxidation of plasma LDL and Lp(a).
Methods. The assay employs rabbit polyclonal antibodies di-
rected against LGE2-protein adducts that form pyrroles, and
alkaline phosphatase-conjugated polyclonal antibodies specific for
apo B or apo (a). It demonstrates a high degree of specificity,
sensitivity and validity.
Results. Epitopes characteristic for LGE2-pyrroles were quan-
tified in patients with end-stage renal disease (ESRD) that had
undergone continuous ambulatory peritoneal dialysis (CAPD)
and in a gender- and age-matched control population. In addition
to finding that both LDL and Lp(a) levels were elevated in CAPD
patients, we also found that plasma Lp(a) but not LDL was more
oxidized in CAPD patients when compared to corresponding
lipoproteins from healthy subjects. Using density gradient ultra-
centrifugation of plasma samples, we found that modified Lp(a)
floats at the same density as total Lp(a).
Conclusions. The results of this study demonstrate that oxida-
tion of plasma Lp(a) is a characteristic of ESRD patients under-
going CAPD. This ELISA may be useful for further investigations
on oxidation of lipoproteins in the circulation of specific patient
populations.
One of the characteristics of end-stage renal disease
(ESRD) is the presence of oxidative stress [1–3]. Mortality
in this patient population is primarily due to coronary
and/or peripheral artery diseases as a result of atheroscle-
rosis [4]. Oxidation of plasma low density lipoproteins
(LDL), claimed to be present in such patients [5], has been
linked to the atherosclerotic process by the ability of such
oxidized (ox-) LDL to induce a number of events in model
systems that are considered to be atherogenic [6]. Increased
plasma levels of ox-LDL would be expected to accelerate
the further oxidation of LDL in the interstitial space of
tissues such as the arterial intima following insudation from
the circulation. Evidence for the presence of ox-LDL in
plasma came from measurements in the circulation of
hydroperoxides [7], thiobarbituric acid reactive substances
(TBARS), conjugated dienes, affinity of lipoproteins for
specific ion exchange matrices [8], autoantibodies [9, 10],
and epitopes specific for oxidized lipid-protein adducts
[11–14]. However, several of these measurements are non-
specific, while others require initial isolation of LDL. Some
studies reported an increased susceptibility to in vitro-
induced oxidation of LDL isolated from plasma of ESRD
patients [9, 15, 16], while others failed to find such an
increase [17, 18].
In contrast to LDL, little attention has been paid to the
possible oxidation of plasma Lp(a) in ESRD patients,
including those on continuous ambulatory peritoneal dial-
ysis (CAPD), even though Lp(a) is believed to be as
susceptible to oxidation under in vitro conditions as is LDL
[19–23]. Oxidation of LDL or Lp(a) is commonly charac-
terized by the formation of aldehydes that react with their
respective apoprotein moieties [6, 24]. Two immunoassays
have been reported that directly measure oxidatively-mod-
ified lipoproteins in plasma samples. One employed anti-
bodies to epitopes specific for MDA-modified proteins
[11–13], and the other to epitopes in specific fractions of
oxidized phosphatidylcholine-modified proteins [14], but
which required first isolating the lipoprotein [11–14]. Given
that MDA modification of proteins requires free radical-
induced scission of lipid hydroperoxides [24], an event
occurring in more extensively-oxidized lipoproteins [24], we
sought a modification of LDL that represented an earlier
stage in the oxidation of lipoproteins, one that would more
likely be still present in the circulation.
Phospholipid endoperoxide formation represents an
early event during oxidation of LDL. It is the result of
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free-radical-induced oxidation of phospholipid-associated
arachidonate in LDL [25]. The structurally-similar prosta-
glandin endoperoxide (PGH2 derived from arachidonate)
rearranges to generate prostaglandins and secoprostanoic
acid levulinaldehyde derivatives, defined as LGE2 [26].
These aldehydes can then react with lysyl residues on
proteins to form adducts that subsequently partition to
form pyrroles [27, 28]. We had previously shown by immu-
nochemical procedures that such formation of LGE2-de-
rived protein-bound pyrroles from arachidonate occurs as a
very early event during oxidation of LDL [29], as contrasted
to MDA modification. Moreover, in preliminary studies we
found that the degree of modification of proteins and
lipoproteins in plasma by LGE2 is far less than the amount
of adduction required to induce uptake by macrophages in
culture [30]. In this present study we have developed a
sandwich ELISA employing polyclonal antibodies to
LGE2-protein pyrroles and polyclonal antibodies to apo B
and apo (a) to quantify the degree of oxidation in plasma
LDL and Lp(a) of CAPD patients and age-matched normal
individuals.
METHODS
Materials
All chemical reagents were purchased from Sigma
Chemical Co. (St. Louis, MO, USA) unless specified
otherwise.
Patient and control populations
Plasma was obtained from patients undergoing CAPD
treatment at the Cleveland Clinic Foundation. All patients
were on CAPD treatment for an average of 30 months and
received 8 to 12 liter of Dianeal® dialysate per day (Baxter
Travenol, Deerfield, IL, USA). Baseline characteristics of
the 27 CAPD patients are summarized in Table 1. Patients
typically received medications for hypertension (primary
calcium channel blockers) and were treated with erythro-
poetin, phosphorus binders, plus iron and vitamin D sup-
plements. The study protocol was approved by the Institu-
tional Review Board, and all patients gave their written
informed consent prior to participation. Control plasma
was obtained from a group of randomly selected volunteers
within the Cleveland Clinic Foundation and was comprised
of 15 subjects with no history of renal disease who were
matched with the CAPD patients for gender and race.
Blood samples
Whole blood was collected by venipuncture into vacu-
tainer tubes (Becton Dickinson & Co., Rutherford, NJ,
USA) containing EDTA (0.15% final concentration) and
placed in an ice bucket. Plasma was then separated by
centrifugation at 3000 rpm. Butylated hydroxytoluene
(BHT), leupeptin, pepstatin and aprotinin were added
immediately to plasma to final concentrations of 40 mM, 35
mM, 5 mM and 18 mg/ml, respectively. Samples were either
used immediately for assaying or quench-frozen in liquid
nitrogen and stored at 270°C.
Lipoprotein isolation and density gradient
ultracentrifugation
LDL was isolated from fresh human plasma by sequen-
tial ultracentrifugation at a 1.019 , d , 1.063 g/ml density
fraction [31]. The LDL was dialyzed against phosphate
buffered saline (PBS), pH 7.4 containing 1 mg/ml EDTA
and 40 mM BHT, filter-sterilized and used for subsequent
modification. Lp(a) was isolated from a male donor with an
Lp(a) plasma level of 30 mg/dl in the density range of 1.050
to 1.110 g/ml, and further purified on Sephacryl S 400-HR
as reported previously [32]. Lp(a) purity was assessed by
agarose gel electrophoresis and by 4 to 12% gradient
SDS-PAGE. The procedure for density gradient ultracen-
trifugation was performed according to Redgrave, Roberts
and West [33] with minor changes. Solutions of NaBr with
decreasing density were layered sequentially from the
bottom to the top into Beckman 14 3 89 mm Ultra-Cleary
tubes (0.5 ml d 5 1.478 g/ml; 2 ml of plasma at d 5 1.21
g/ml, 3 ml d 5 1.1 g/ml, 3 ml d 5 1.05 g/ml and 2 ml d 5
1.006 g/ml). The tubes were centrifuged in a Beckman
SW-41 rotor at 39, 000 rpm for 44 hours. After centrifuga-
tion, 22 fractions were collected sequentially from the
bottom of the tubes. The densities of the fractions were
measured by refractometry on parallel tubes.
Low density lipoprotein and Lp(a) modification
LGE2 ([R]-acetyl-9[R]-formyl-12[S]-hydroxy-5[Z],10[E]-
heptadeca-dienoic acid) and 3H-labeled LGE2 were pre-
pared as described previously [34, 35]. 0.5 ml of LDL or
Lp(a) (0.5 mg/ml) in PBS/EDTA were combined with 0.5
ml 3H LGE2 (0.2 mg/ml) in PBS and incubated at 37°C for
12 hours. The mixture was then dialyzed against PBS/
EDTA, centrifuged for 10 minutes at 10,000 g, and steril-
ized by filtration. The amount of protein was determined by
the bicinchoninic acid assay [36], and the amount of LGE2
Table 1. Characteristics of CAPD patients and age matched controls
Controls
(N 5 15)
CAPD
(N 5 27)
Age 48 6 10 52 6 15
Sex (m/f) 6/9 14/13
Race (w/b/others) 8/7 14/11(1 Spanish/1 Indian)
Diabetes 0 48%
Presence of cardiovascular 0 41%
disease
Creatinine clearance — 76.8 6 39.4
KT/V — 2.2 6 0.6
Creatinine mg/ml — 9.8 6 3.5
Duration of PD procedure 0 30 6 21 months
LDL concentration mg/dl 92.2 6 19.1 112.7 6 31.6a
Lp(a) concentration mg/dl 16.1 6 13.6 30.9 6 23.4a
Data are presented as mean 6 SD.
Comparison of Lp(a) levels was performed on log transformed data.
a Significance p , 0.05 vs. control group
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bound was assessed by quantifying the radioactivity associ-
ated with lipoprotein.
Antibodies and conjugates
Goat anti-human plasma LDL was purchased from Be-
thyl Laboratories (Montgomery, TX, USA). Affinity-puri-
fied goat anti-LDL IgG was obtained using LDL-Sepharose
prepared by coupling of LDL to CNBr-activated Sepha-
rose®-4B (Pharmacia, Stockholm, Sweden) as described in
detail elsewhere [37]. Goat anti-human plasma Lp(a) was
purchased from International Enzymes, Inc. (Fallbrook,
CA, USA) and demonstrated no crossreactivity with human
plasminogen or apo B. Alkaline phosphatase conjugates of
anti-LDL and anti-Lp(a) were prepared as described pre-
viously [37]. Preparation of rabbit antibodies to keyhole
limpet hemocyanin (KLH)-LGE2 was described by us
earlier [38]. The IgG fraction was purified from the serum
using protein G-agarose [ImmunoPure® (G) Immobilized
Protein G; Pierce, Rockford, IL, USA] according to the
manufacturer’s protocol. The concentration of isolated IgG
was determined by absorbance at 280 nm. Specificity of
antibodies to LGE2 was assessed previously in competitive
inhibition studies [38]. No crossreactivity of this antibody
was shown with LDL, MDA-modified LDL, or HNE-
modified LDL.
Measurement of LDL and Lp(a) concentrations
Lp(a) concentrations in plasma samples were measured
according to Fless, Snyder and Scanu [39] and expressed as
Lp(a) mass per dl of plasma. In this method goat anti-
human apo (a) polyclonal antibodies were used to capture
Lp(a) in samples diluted 1/100 to 1/400 in carbonate buffer.
Affinity-purified goat anti-human LDL (apo B) conjugated
to alkaline phosphatase was used to detect the bound
Lp(a). This method detects Lp(a) isoforms with equal
sensitivity and does not detect plasminogen [39]. This same
method was used for measurement of LDL concentrations
with the following modifications: the coating antibody was
goat anti-LDL, plasma samples were diluted 1500-fold, and
standard LDL concentrations ranged from 0.25 to 2 mg/ml.
Absorbance was read with a Bio-Rad Model 3550 micro-
plate reader at 405 nm using 595 nm as the reference
wavelength. The sigmoidal dose-response curve was trans-
formed using the logit function as described by Tijssen [40]
and analyzed by least square regression.
Detection of immunoreactive LGE2-LDL and LGE2-Lp(a)
by ELISA
Microtiter plates (Corning, Cambridge, MA, USA) were
coated with 200 ml of anti LGE2 IgG (20 mg/ml) in PBS
overnight at 4°C, followed by blocking with 300 ml of PBS
containing 3% bovine serum albumin (BSA), for two hours
at 37°C. Following washing of the plates with PBS, a 200 ml
test sample, prepared by diluting plasma 750- to 1500-fold
in PBS containing 3% BSA, was added to plates and
incubated for 90 minutes at 37°C. A 200 ml sample of
LGE2-modified LDL or LGE2-modified Lp(a), in a con-
centration range of 5 ng to 2 mg, was also added and served
as standards. Plates were subsequently washed three times
with PBS containing 0.1% Tween 20 and two times with
PBS. Two hundred microliters of goat anti-LDL or goat
anti-Lp(a) conjugated to alkaline phosphatase (diluted
1/500 in PBS/BSA) were then added, and plates incubated
at 37°C for 90 minutes. After washing the plates with PBS,
200 ml of p-nitrophenyl phosphate in Tris buffer (SIGMA
FASTy pNPP tablets; Sigma) was added to each well. The
plates were then placed in a dark chamber, and the enzyme
reaction was allowed to proceed for 30 to 60 minutes at
37°C. Absorbance was read as reported above. The sigmoi-
dal dose-response curve was transformed using the logit
function and analyzed by least square regression.
Other methods
Proteins were measured by the bicinchoninic acid assay
(Pierce) using bovine serum albumin as a standard [36].
Oxidized LDL was prepared by incubation of LDL (0.3
mg/ml) with 5 mM copper sulfate at 37°C for 18 hours and
subsequent dialysis against PBS/EDTA.
Statistical analysis
A log transformation of Lp(a) concentration data was
used to approach normal distribution. Differences were
assessed by an unpaired Student’s t-test.
RESULTS
ELISA for quantification of oxidized plasma LDL or
Lp(a)
As was shown previously by us [38], antibodies generated
against KLH that had been modified with LGE2 specifically
recognize pyrrole epitopes on LGE2-protein adducts [38].
No detectable crossreactivity of LGE2-KLH antibodies was
found with MDA-LDL or HNE-LDL [38]. During prelim-
inary studies we found that the sensitivity of our ELISA was
insufficient to measure oxidized LDL and Lp(a) in plasma
when we used an initial immunoprecipitation of LDL or
Lp(a) by anti-LDL or anti-Lp(a) respectively, and subse-
quent detection of LGE2-protein adducts by a phospha-
tase-conjugated LGE2-KLH antibody. However, as shown
previously [14], the sensitivity of the assay can be signifi-
cantly increased by first absorbing modified lipoproteins
with specific antibodies recognizing chemically-modified
macromolecules, and then using phosphatase-conjugated
antibodies to native lipoproteins to detect and quantify the
amount of bound lipoprotein. We used this second ap-
proach and found that LGE2-modified LDL and LGE2-
modified Lp(a) bind to wells coated with anti-LGE2-KLH
in a dose-dependent fashion up to 0.5 mg/ml of LDL or
Lp(a) (Fig. 1 A, B). When nonimmune rabbit IgG was used
to precoat wells instead of anti-LGE2-KLH, only negligible
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lipoprotein binding was observed. As such, the assay system
measures the number of lipoprotein particles that contain
at least one LGE2-protein adduct. Excess amounts of
LGE2-modified HSA (100-fold) inhibited LGE2-modified
lipoprotein binding to anti-LGE2-KLH by 90%. Cu
11-
oxidized LDL demonstrated a degree of binding to anti-
LGE2-KLH which was similar to that of LGE2-modified
LDL (Fig. 1C), suggesting that LGE2-protein pyrroles were
formed in LDL by oxidation, as was shown previously [29].
The intra- and inter-assay coefficient of variation for the
determination of LGE2-LDL and LGE2-Lp(a) was ,5%
and 10%, respectively. The high sensitivity of the assay was
achieved by virtue of the fact that each modified lipopro-
tein particle that was attached to wells precoated with
anti-LGE2-KLH, can bind a large number of anti-apo B or
anti-apo (a) molecules. In this ELISA the conjugated
antibodies against apo B or apo (a) are unable to detect
other proteins that could bind to anti-LGE2-KLH. Thus,
our assay will detect all apo B or apo (a) modified by LGE2
including lipoprotein-free fragments of apo B or apo (a).
Since we were measuring the amount of bound apoli-
poprotein immunoreactivity after trapping modified li-
poproteins by anti-LGE2-KLH, we needed to determine
whether anti-apo B and anti-apo (a) recognized the modi-
fied lipoproteins to the same degree as native lipoproteins.
At a level of modification used in this study, apo B
recognition by anti-apo B was not changed appreciably, nor
was apo (a) recognition by anti-apo (a) (data not shown).
Oxidation of LDL and Lp(a) in CAPD and in a control
population
Since in preliminary experiments we found that quench-
freezing of plasma samples in liquid nitrogen did not
induce significant changes in measurement of lipoproteins
Fig. 1. Determination of LDL-LGE2 (A),
Lp(a)-LGE2 (B), and oxidized LDL (C) by a
sandwich ELISA using a rabbit polyclonal
antibody to LGE2-KLH pyrroles as a coating
antibody and anti-apo B or anti-apo (a) as the
revealing antibody. Modified lipoproteins were
prepared as described in the Methods section.
Microtiter wells were precoated with 4 mg/well
of anti-LGE2-KLH IgG (open symbols) or
nonimmune rabbit IgG (closed symbols). After
the blocking of wells with BSA, 200 ml of
various concentrations of modified lipoproteins
were added to the microtiter wells. LDL-LGE2
and oxidized LDL that were trapped by anti-
LGE2-KLH, were then detected by a goat anti-
LDL-phosphatase conjugate, and Lp(a)-LGE2
by a goat anti-apo (a)-phosphatase conjugate.
Each point represents the mean of duplicate
determinations.
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or LGE2-lipoprotein immunoreactivity, we performed all
subsequent measurements on such quench-frozen samples.
The plasma from 27 CAPD patients and 15 control subjects
was assayed to determine the levels of LDL and Lp(a) and
the levels of oxidized LDL and Lp(a), indicated by the
amounts of LGE2-LDL and LGE2-Lp(a) levels, respec-
tively. As seen in Table 1, the mean levels of both LDL and
Lp(a) were statistically significantly elevated when com-
pared to corresponding levels in the control population.
The level of plasma LGE2-LDL ranged from 2.5 to 5.5
mg/dl, and from 1.9 to 7.1 mg/dl in the control group and in
the CAPD group, respectively (Fig. 2A). The level of
LGE2-LDL was found to be 19% higher in the CAPD
group than in the control group (P , 0.05). However, the
level of LGE2-LDL when normalized for equal concentra-
tions of plasma LDL was about the same in the CAPD
patients as in the control group (Fig. 2B), since the mean
plasma concentration of LDL was higher in patients than in
controls (Table 1).
The levels of LGE2-modified Lp(a) varied from unde-
tectable to 11.9 mg/dl in the control group and from
undetectable to 27.8 mg/dl in the CAPD group (Fig. 3A).
The mean level of LGE2-Lp(a) was found to be 2.4 times
higher in the CAPD patient group than in the control group
(Fig. 3A, P , 0.05). Since this difference may merely reflect
the difference in Lp(a) concentrations, as was found for
LDL, we again compared the LGE2-Lp(a) level in the two
groups after normalizing for their respective Lp(a) concen-
trations. We found that such normalization of data slightly
decreased the difference between the CAPD group and the
control group, but normalized LGE2-Lp(a) levels were still
significantly higher in the CAPD group than in the control
group (1.6 times, P , 0.05, Fig. 3B). Thus, not only is the
total amount of LGE2-Lp(a) increased in CAPD patients,
but the percent of Lp(a) particles that are associated with
at least one LGE2-protein epitope is also increased.
Since many of the CAPD patients had diabetes and/or
CVD, which themselves could be causative factors for the
oxidation of Lp(a), we separated the CAPD group into
those with or without documented CVD, as well as those
with or without diabetes. Although no significant differ-
ences in Lp(a) levels were found in the subgroups with and
without diabetes, we did find that Lp(a) levels were higher
in the CVD subgroup relative to the subgroup without
CVD, but the degree of significance was borderline (Table
2). When subsequently examining the level of oxidation of
Lp(a) in such subgroups, we found that there was no
statistically significant difference in LGE2-Lp(a) level be-
tween the CAPD subgroups with or without CVD, nor
those with- and without diabetes (Table 2). This result
suggests that the oxidation of Lp(a) was probably not the
result of CVD nor diabetes. The level of oxidation of Lp(a)
was still higher in the different CAPD subgroups relative to
the control group (Table 2), although not all reached the
P , 0.05 level of significance. When KT/V values, creati-
nine clearance levels, and time of dialysis for each CAPD
patient were each correlated with corresponding LGE2-
Lp(a) values, no associations could be found (not shown).
Thus, it is unlikely that the dialysis procedure was respon-
sible for the oxidation of Lp(a). This would leave renal
Fig. 2. Concentrations of LGE2-modified LDL in the plasma of patients with ESRD undergoing CAPD and in a control group. Plasma samples from
27 patients (f) and from 15 age-matched control individuals (E) were obtained and subjected to measurements described in the Methods section. The
anti-apo B-phosphatase conjugate was used for the detection of lipoproteins bound to microtiter wells. The average concentration of LGE2-LDL was
4.09 6 0.81 mg/dl in plasma of controls, and 4.86 6 1.22 mg/dl in those of patients (A). The difference was statistically significant as assessed by an
unpaired Student’s t-test. Normalization of LGE2-LDL concentrations was performed by dividing each value by its corresponding LDL concentration
(B). Mean values were 0.045 6 0.013 for patients and 0.045 6 0.008 for controls. In A, P , 0.05; in B, P 5 0.92.
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failure as the most likely factor responsible for this oxida-
tion.
It was shown previously that some apo (a) in Lp(a) in
human plasma can be detected in a fragmented state, and
therefore can be found in non-lipoprotein fractions [41].
This was particularly true for ESRD patients on dialysis
[42]. If Lp(a) oxidation induces free-radical scission of apo
(a), fragments should also be oxidatively modified and,
therefore, be detected by our ELISA. Since our method of
measuring of LGE2-Lp(a) does not discriminate between
free apo (a) and apo (a) within an Lp(a) particle, we
attempted to separate Lp(a) and fragments of apo (a) by
density gradient ultracentrifugation with subsequent detec-
tion of LGE2-apo (a) immunoreactivity in the different
density fractions. If oxidatively modified apo (a) fragments
were present in plasma samples of CAPD patients tested,
they should be detected in a non-lipoprotein fraction (d .
1.21 g/ml) by our method. Fresh plasma samples from four
CAPD patients were therefore individually subjected to
density gradient ultracentrifugation and the density distri-
bution of Lp(a) and LGE2-Lp(a) determined. The hydrated
density of Lp(a) peaks varied from 1.08 to 1.1 g/ml in
different samples. Lp(a) immunoreactivity was not found at
a non-lipoprotein density in three of the four samples (Fig.
4A). However, in one sample a small additional peak was
found at a density higher than that of intact Lp(a) (Fig. 4B).
Since our revealing antibody is specific for apo (a), this
peak probably represents apo (a) not associated with an
intact Lp(a) particle. In this sample, as in others, there was
little if any change in the hydrated density distribution of
Lp(a) particles with LGE2-protein pyrroles when compared
to that of total Lp(a). Furthermore, no apo (a) with
LGE2-protein epitopes was found in a density . 1.21 g/ml
where fragments of apo (a) would appear. These results
suggest that the immunoreactive LGE2-Lp(a) being mea-
sured in our ELISA do not represent fragments of Lp(a),
but rather intact Lp(a) particles.
DISCUSSION
The major result of this study is that Lp(a), but not LDL,
is oxidized in plasma of CAPD patients. That such oxida-
tion has occurred is not unexpected, since oxidative stress
has been shown to be a characteristic of ESRD [1–3]. It
should be noted that any oxidation of lipoproteins in the
circulation would be at a level below that required for it to
be a ligand for scavenger receptors on tissue macrophages.
Fig. 3. Concentrations of LGE2-modified Lp(a) in the plasma of patients with ESRD undergoing CAPD and in controls. An anti-apo (a)-phosphatase
conjugate was used to reveal bound lipoproteins (A). The average concentration of LGE2-Lp(a) was 11.28 6 8.74 mg/dl and 4.77 6 3.89 mg/dl in patient
and control plasma, respectively (P , 0.01). A log transformation of data was used to calculate statistical differences. Normalization of LGE2-Lp(a)
concentrations was performed by dividing each value by its corresponding Lp(a) concentration (B). Mean values were 0.443 6 0.238 for patients and
0.275 6 0.141 for controls (P , 0.05).
Table 2. Level of Lp(a) and Lp(a)-LGE2 in specific subgroups of CAPD patients and in the control population
Controls
(N 5 15)
CAPD patients
with diabetes
(N 5 13)
without diabetes
(N 5 14)
with CVD
(N 5 11)
without CVD
(N 5 16)
Lp(a) mg/dl 16.1 6 13.6 27.9 6 21.3 33.5 6 25.0a 36.7 6 24.5b 26.8 6 21.9
Lp(a)-LGE2 4.8 6 3.9 9.8 6 8.4
a 12.7 6 9.0b 10.2 6 7.1a 12.6 6 9.8b
Data are presented as mean 6 SD. Comparison of Lp(a) levels was performed on log-transformed data.
a P , 0.05 vs. control group
b P , 0.01 vs. control group
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Indeed, if oxidation of Lp(a) were to increase to such
threshold levels, such particles would be rapidly removed
from the circulation by Kupffer cells after passage through
the liver [43]. We had shown previously that when LDL was
modified directly with LGE2, recognition of such modified
LDL by macrophages in culture occurred only when about
30 or more molecules of LGE2 formed pyrroles with lysine
residues on one molecule of apo B in LDL [30]. Thus, any
measurement of oxidation of lipoproteins in this study
represents only an initial stage of oxidation.
Our results showing no oxidation of LDL in CAPD
patients are in agreement with those of Westhuyzen, Sal-
tissi and Healy [17], who found no evidence for the
oxidation of plasma LDL in ESRD patients. However, in
those studies hemodialysis rather than CAPD patients were
investigated. Our results on the oxidation of Lp(a) appear
to be consisitent with those of Kotani et al [12]. Using an
antibody to MDA-protein adducts, this group demon-
strated that the greatest modification of apo B-containing
lipoproteins in plasma was found at a hydrated density in
which Lp(a) is normally found. However, these authors
interpreted their results to mean that the modified apo B in
their study represented small dense LDL [12] and not
Lp(a).
It is unclear as to why Lp(a), but not LDL, was more
oxidized in the plasma of CAPD patients in this study. One
explanation is that Lp(a) itself is more prone to oxidation
than LDL, although the data in the literature on such a
comparison give conflicting conclusions [19, 21, 22, 44].
Another possibility is that Lp(a) is more oxidized in ESRD
patients due to a lower plasma clearance of Lp(a) than of
LDL [45]. By increasing the residence time of Lp(a) in the
circulation, these particles would be expected to be more
prone to oxidation. Since Lp(a) is capable of binding to
endothelial cells and platelets to a greater degree than LDL
[46], it is also possible that such binding can facilitate Lp(a)
oxidation in vivo, thereby resulting in preferential oxidation
of Lp(a). The increase in oxidation of Lp(a) found in our
ESRD patients could have been due to the dialysis proce-
dure, or to the presence of such risk factors as CVD or
diabetes. However, since we did not find an association
between the oxidation of Lp(a) and any of these factors, it
is unlikely that they induced this oxidation. It seems more
likely that the increased oxidation of Lp(a) is the result of
renal failure, consistent with the oxidative stress that char-
acterizes this disease process [1–3].
Oxidized Lp(a) possesses several atherogenic properties
that it shares with oxidized LDL, which could be partially
responsible for the association between elevated Lp(a)
levels and CVD in several patient populations including
patients with ESRD undergoing hemodialysis [47] or
CAPD [48]. One of them is an induction of the cell
adhesion molecule Mac-1 on the monocyte surface [44],
responsible for enhanced binding of monocytes to endothe-
lial cells. This is followed by entry of these monocytes into
the arterial intima and their development into tissue mac-
rophages [49]. Finally, recognition of more extensively-
oxidized Lp(a) by the scavenger receptor on tissue macro-
phages will occur, leading to lipid loading of these cells [21].
Both ox-LDL and ox-Lp(a) were shown to stimulate the
Fig. 4. Density gradient profiles of Lp(a) and LGE2-Lp(a) in plasma samples from patients with ESRD undergoing CAPD. Two milliliters of fresh
plasmas from four individual patients was subjected to density gradient ultracentrifugation as described in the Methods section. The fractions were
collected from the bottom of the tube, and their densities were measured by refractometry. Apo (a) immunoreactivity was measured by first coating the
plates with anti-apo (a) and then revealing the bound apo (a) with the conjugated anti-apo (a). LGE2-apo (a) immunoreactivity was measured by first
coating wells with anti-LGE2-KLH and then revealing with anti-apo (a). It is presented as absorbance at 405 nm. Two of the four samples studied are
presented. Each point represents the mean of triplicate determinations. Symbols are: () apo (a); (L) LGE2-apo (a).
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release of renin from juxtaglomelar cells [50]. However,
ox-Lp(a) also possesses properties not shared by ox-LDL. It
exhibits increased binding to the plasminogen receptor,
thereby potentially competing with plasminogen for this
site, and ultimately inhibiting fibrinolysis [51]. Also, ox-
Lp(a) is capable of increasing the production of plasmino-
gen activator inhibitor-1 by the endothelial cells [46].
Finally, ox-Lp(a) was shown to be more potent than
ox-LDL in inhibiting endothelium-dependent vasodilation
[52].
In conclusion, this study describes a sandwich ELISA for
measuring oxidation of LDL and Lp(a) in plasma. We have
used it to provide evidence that Lp(a), but not LDL, is
more oxidized in patients with ESRD undergoing CAPD
when compared to corresponding lipoproteins from healthy
subjects. Additional studies are still needed to evaluate the
significance of a relationship between ESRD and lipopro-
tein oxidation, as well as a possible role of additional
clinical factors in this relationship.
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APPENDIX
Abbreviations used in this article are: apo B, apolipoprotein B; apo (a),
apolipoprotein (a); BHT, butylated hydroxytoluene; CAPD, continuous
ambulatory peritoneal dialysis; ELISA, enzyme-linked sandwich immu-
nosorbent assay; ESRD, end-stage renal disease; KLH, keyhole limpet
hemocyanin; LDL, low density lipoprotein; LGE2, [R]-acetyl-9[R]-formyl-
12[S]-hydroxy-5[Z],10[E]-heptadeca-dienoic acid; Lp(a), lipoprotein(a);
PBS, phosphate buffered saline; TBARS, thiobarbituric acid reactive
substance.
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